Clinical Trial Update: Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating CAR-T cells targeting CD19 and CD22 for relapsed or refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Lymphoma B-cell

Drugs mentioned

• CD19 and CD22-targeting CAR-T cells

Snippet

Sponsor: Shanxi Province Cancer Hospital | Conditions: Lymphoma, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN